Abstract Body

With recent shifts towards widespread effective prevention of mother-to-child transmission (PMTCT) coverage, and HIV birth testing implementation in South Africa allowing for initiation of antiretroviral therapy (ART) in the first weeks of life, the virologic and immunologic response of infants started on ART at <3 months of age may be different to previous periods. Evidence from large cohorts of infants receiving early ART outside of clinical trial environments is limited. We described the changes in virologic and immunologic outcomes during the first 6 months on ART according to time period of ART initiation.

We analysed data from a retrospective cohort of HIV-infected infants who started ART aged <12 weeks from 2006-2016 at 8 South African sites within IeDEA-SA, and had ≥1 viral load (VL) measurement between 4-9 months on ART. Descriptive statistical analysis and logistic regression were conducted to describe viral suppression at 6 months on ART and identify determinants. We defined viral suppression as VL <400 copies/ml (cpm) and compared VL outcomes of infants who initiated ART in 2006-2009, 2010-2012 and ≥ 2013.

Of 710 HIV-infected infants included, 56% were female, median age at ART initiation was 9 weeks (Interquartile range (IQR): 5-11), median log10 VL and CD4% were 5.86 (IQR: 4.8-6.4) cpm and 26.4 (IQR 18.6-37) respectively. The proportion of infants that achieved viral suppression by 6 months on ART decreased from 66% in 2006-09 to 50% in 2013-16 (P<0.015) and from 78% in 2006-09 to 58% in 2013-16 among 410 infants with additional VL measured at 12 months on ART. Median CD4 count by 6 months on ART was increased slightly among infants starting ART in 2013-16 vs. in earlier years (2096 vs. 1588 cells/mm3, p<0.001). VL >1 million cpm and ART initiation ≥2013 were associated with lower odds of viral suppression at 6 months on ART (adjusted Odds Ratio (aOR): 0.43; 95% CI: 0.24-0.75 and aOR: 0.33; 95% CI: 0.18-0.61, respectively).

Poorer virologic suppression in infants who initiated ART ≥ 2013 compared to earlier years is a major concern, especially as infants starting in recent years had higher CD4% and lower VL at ART initiation. Further research is needed to understand reasons for worse VL outcomes in recent years. Ongoing monitoring of these infants is crucial to determine the long-term impact of poorer early viral suppression.